- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01746420
Phase II Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis
A Phase II Randomized, Single Ascending Dose, Double-blinded, Placebo Controlled, Multi-center Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Methodology: Randomized, single ascending dose, double-blinded, placebo controlled, multi-center study
Study Center(s): 6
Number of Subjects: 100
Diagnosis and Main Inclusion Criteria: Lateral epicondylitis; male and female subjects 21 -80 years of age
Study Drug, Dose, Regimen:
Dose A: sodium acetate buffer alone - placebo control Dose B: sodium acetate buffer + 0.45 mg rhPDGF-BB Dose C: sodium acetate buffer + 0.75 mg rhPDGF-BB Dose D: sodium acetate buffer + 1.5 mg rhPDGF-BB Dose E: sodium acetate buffer + 3.0 mg rhPDGF-BB
Duration and Route of Administration: Single administration dose by injection into the extensor carpi radialis brevis (ECRB)
Duration of Follow-up: 24 weeks (6 months) post-operative follow-up
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85023
- Arizona Research Center
-
Tucson, Arizona, Verenigde Staten, 85712
- Tucson Orthopaedic Institute
-
-
Arkansas
-
Jonesboro, Arkansas, Verenigde Staten, 72401
- NEA Baptist Clinic
-
-
Florida
-
Bradenton, Florida, Verenigde Staten, 34209
- Coastal Orthopedics & Sports Medicine
-
Tampa, Florida, Verenigde Staten, 33637
- Foundation for Orthopaedic Research and Education
-
-
North Carolina
-
Charlotte, North Carolina, Verenigde Staten, 28207
- OrthoCarolina
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Subject has signed the Institutional Review Board (IRB) approved Informed Consent Form specific to this study prior to enrollment
- Subject has a clinical diagnosis of lateral epicondylitis
- Subject's symptoms can be reproduced with resisted supination or wrist dorsiflexion
Subject's symptoms have persisted for at least 3 months despite conservative treatment that includes one or combinations of:
- Physical therapy
- Splinting
- Nonsteroidal antiinflammatory drug (NSAID)
- Corticosteroid injection
- Subject is independent, ambulatory, and can comply with all post-injection evaluations and visits
- Subject is 21-80 years of age and considered to be skeletally mature
Exclusion Criteria:
- Subject has undergone previous corticosteroid injection therapy to the effected elbow in less than three months prior to enrollment
- Subject has received previous Platelet Rich Plasma (PRP) injection to the affected elbow
- Subject is deemed to require a corticosteroid injection into the affected elbow during the course of the study
- Subject uses chronic medications known to affect the skeleton (e.g. glucocorticoid usage >10mg/day)
- Subject has undergone surgical intervention to the affected elbow for the treatment of lateral epicondylitis
Subject has a positive medical history of any of the following:
- medial epicondylitis
- radial tunnel syndrome
- carpal tunnel syndrome
- septic or gouty arthritis
- cervical radiculopathy
- trauma to the affected elbow within the past 6 weeks
- neuromuscular or musculoskeletal deficiency, which limits the ability to perform functional measurement (e.g. grip strength test)
- Subject currently has an acute infection at the injection site
- Subject has tested positive or been treated for a malignancy in the past or is suspected of having a malignancy or are currently undergoing radio- or chemotherapy treatment for a malignancy anywhere in the body, whether adjacent to or distant from the proposed rhPDGF-BB Injection treatment site
- Subject is physically or mentally compromised (e.g. currently being treated for a psychiatric disorder, senile dementia, Alzheimer's disease, etc.) to the extent that the Investigator judges the subject to be unable or unlikely to remain compliant
- Subject has an allergy to yeast-derived products
- Subject has received an investigational therapy or approved therapy for investigational use within 30 days of injection procedure or during the follow-up phase of this study
- Subject is a prisoner, or is known or suspected to be transient
- Subject's condition represents a worker's compensation case
- Subject is currently involved in a health-related litigation procedure
- Subject has documented evidence of a history (e.g. liver testing) of drug/alcohol abuse within the 12 months prior to screening for study entry
- Subject is pregnant, or able to become pregnant but not practicing a medically-accepted form of birth control, and/or intending to become pregnant during this study period
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Placebo-vergelijker: Placebo Control
Dose A - sodium acetate buffer (0 mg rhPDGF-BB)
|
sodium acetate buffer (0 mg rhPDGF-BB)
|
Experimenteel: 0.45 mg rhPDGF-BB
Dose B - sodium acetate buffer + 0.45 mg rhPDGF-BB
|
Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
|
Experimenteel: 0.75 mg rhPDGF-BB
Dose C - sodium acetate buffer + 0.75 mg rhPDGF-BB
|
Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
|
Experimenteel: 1.5 mg rhPDGF-BB
Dose D - sodium acetate buffer + 1.5 mg rhPDGF-BB
|
Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
|
Experimenteel: 3.0 mg rhPDGF-BB
Dose E - sodium acetate buffer + 3.0 mg rhPDGF-BB
|
Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Elbow Pain Assessments (VAS), Treated Subjects
Tijdsspanne: Baseline, 2, 4, 8, 12, and 24 weeks
|
Subjects were asked to report current pain level at the fusion site on a 100 mm Visual Analog Scale (with 0 being no pain and 100 being worst pain imaginable).
|
Baseline, 2, 4, 8, 12, and 24 weeks
|
Disabilities of the Arm, Shoulder and Hand (DASH), Treated Subjects
Tijdsspanne: Baseline, 4, 8, 12, and 24 weeks
|
The disabilities of the arm, shoulder and hand (DASH) questionnaire is a self-administered region-specific outcome instrument developed as a measure of self-rated upper-extremity disability and symptoms.
The DASH consists mainly of a 30-item disability/symptom scale, scored 0 (no disability) to 100.
|
Baseline, 4, 8, 12, and 24 weeks
|
Total Score Patient Rated Tennis Elbow Evaluation (PRTEE), All Treated Subjects
Tijdsspanne: Baseline, 4, 8, 12, and 24 weeks
|
The Pain and disability measured by the Patient Rated Tennis Elbow Evaluation (PRTEE) is a 15-item questionnaire designed to measure forearm pain and disability in patients with lateral epicondylitis (also known as "tennis elbow"). The PRTEE allows patients to rate their levels of tennis elbow pain and disability from 0 to 10, and consists of 2 subscales:
In addition to the individual subscale scores, a total score can be computed on a scale of 100 (0 = no disability), where pain and functional problems are weighted equally |
Baseline, 4, 8, 12, and 24 weeks
|
Grip Strength Test, All Treated Subjects
Tijdsspanne: Baseline, 4, 8, 12, and 24 weeks
|
Grip strength testing will be performed to evaluate changes in the strength and sincerity of effort as a result of treatment for lateral epicondylitis.
Testing will be performed to assess the pain-free grip strength (performing the test until discomfort is felt) and maximum grip strength (performing the test to the maximum of their ability).
The test will be performed while the patient is standing with the elbow in full extension, as this position has been used to assess grip strength in patients with lateral epicondylitis.
A Jamar Plus+ Digital Hand Dynamometer with the grip in the second position will be used because the second position has been assumed to be the most reliable and consistent position.
Patients will be asked to perform three repetitions of each test (pain-free and maximum) at each study interval and the mean score will be calculated and used for analysis.
|
Baseline, 4, 8, 12, and 24 weeks
|
Maximum Grip Strength, Treated Subjects
Tijdsspanne: Baseline, 4, 8, 12, and 24 weeks
|
A higher grip strength score indicates an improvement.
A positive change from baseline indicates an improvement.
Grip strength testing will be performed to evaluate changes in the strength and sincerity of effort as a result of treatment for lateral epicondylitis.
Testing will be performed to assess the pain-free grip strength (performing the test until discomfort is felt) and maximum grip strength (performing the test to the maximum of their ability).
The test will be performed while the patient is standing with the elbow in full extension, as this position has been used to assess grip strength in patients with lateral epicondylitis.
A Jamar Plus+ Digital Hand Dynamometer with the grip in the second position will be used because the second position has been assumed to be the most reliable and consistent position.
Patients will be asked to perform three repetitions of each test (pain-free and maximum) at each study interval and the mean score will be calculated and used for analysis.
|
Baseline, 4, 8, 12, and 24 weeks
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Edward Akelman, MD, Brown University
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Wonden en verwondingen
- Musculoskeletale aandoeningen
- Spierziekten
- Pees verwondingen
- Tendinopathie
- Arm verwondingen
- Tendinopathie van de elleboog
- Tennis elleboog
- Fysiologische effecten van medicijnen
- Angiogenese modulerende middelen
- Groei stoffen
- Anticoagulantia
- Angiogenese-inducerende middelen
- Becaplermin
Andere studie-ID-nummers
- BMTI-2010-02
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Laterale epicondylitis
-
Hospital for Special Surgery, New YorkActief, niet wervendLaterale epicondylitis | Laterale epicondylitis, niet-gespecificeerde elleboog | Laterale epicondylitis, linkerelleboog | Laterale epicondylitis, rechterelleboog | Laterale epicondylitis (tenniselleboog) Bilateraal | Mediale epicondylitis | Mediale epicondylitis, rechterelleboog | Mediale epicondylitis...Verenigde Staten
-
University of CadizNog niet aan het wervenTendinopathie van de elleboog | Epicondylitis | Epicondylitis, lateraal | Epicondylitis van de elleboog
-
Universidad Rey Juan CarlosVoltooid
-
University of CadizVoltooid
-
University of CadizVoltooid
-
Mennallah Ahmed Mohamed Anwar ElgendyNog niet aan het werven
-
McMaster UniversityArthrex, Inc.; The Physicians' Services Incorporated Foundation; Radiological Society...BeëindigdLaterale epicondylitis (tenniselleboog)Canada, Verenigde Staten
-
Haseki Training and Research HospitalVoltooidLaterale epicondylitis (tenniselleboog)Kalkoen
-
Johns Hopkins UniversityIngetrokkenLaterale epicondylitis | Tennis elleboog | Tendinopathie van de elleboog | Mediale epicondylitis | Golferselleboog
-
International Clinical Research InstituteVoltooidEpicondylitis van de elleboogVerenigde Staten
Klinische onderzoeken op Placebo
-
SamA Pharmaceutical Co., LtdOnbekendAcute bronchitis | Acute bovenste luchtweginfectieKorea, republiek van
-
National Institute on Drug Abuse (NIDA)VoltooidCannabisgebruikVerenigde Staten
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyVoltooidMannelijke proefpersonen met diabetes type II (T2DM)Duitsland
-
Heptares Therapeutics LimitedVoltooidFarmacokinetiek | Veiligheid problemenVerenigd Koninkrijk
-
Longeveron Inc.BeëindigdHypoplastisch linkerhartsyndroomVerenigde Staten
-
Texas A&M UniversityNutraboltVoltooidGlucose and Insulin Response
-
ItalfarmacoVoltooidBecker spierdystrofieNederland, Italië
-
Soroka University Medical CenterVoltooid
-
Regado Biosciences, Inc.VoltooidGezonde vrijwilligerVerenigde Staten